接受依库珠单抗(Soliris)治疗的患者尽管接种了脑膜炎球菌疫苗,仍面临侵袭性脑膜炎球菌病的高风险
美国2008-2016年发现16例接受依库珠单抗治疗者发生脑膜炎球菌病,其中11例由不可分群脑膜炎奈瑟菌引起,14例有接种疫苗记录。尽管接种疫苗,患者仍持续存在风险,部分医生和机构建议治疗期间进行抗菌预防。
要点
- 依库珠单抗治疗者脑膜炎球菌病发病率增加1000至2000倍。
- 美国2008-2016年16例患者中11例由不可分群脑膜炎奈瑟菌引起。
- 14例患者在发病前有接种至少1剂脑膜炎球菌疫苗的记录。
核心结论
- 接受依库珠单抗治疗的患者即使接种了脑膜炎球菌疫苗,仍面临脑膜炎球菌病风险。
研究设计与样本
- 美国2008-2016年对依库珠单抗受者中脑膜炎球菌病病例的识别。
主要发现
- 美国2008-2016年共识别16例依库珠单抗受者发生脑膜炎球菌病,其中11例由不可分群脑膜炎奈瑟菌引起。
- 16例患者中14例有发病前接种至少1剂脑膜炎球菌疫苗的记录。
关键数值与推荐
- 使用依库珠单抗与脑膜炎球菌病发病率增加1000至2000倍相关。
- 推荐接受依库珠单抗的患者在开始治疗前接种脑膜炎球菌疫苗。
临床怎么用
- 美国部分医疗提供者及其他国家公共卫生机构建议在依库珠单抗治疗期间进行抗菌预防,许多患者预计需终身治疗。
- 对所有接受依库珠单抗治疗的患者,无论疫苗接种或抗菌预防状态如何,提高警惕、早期就医和快速治疗任何与脑膜炎球菌病一致的症状至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States during 2008-2016; among these, 11 were caused by nongroupable Neisseria meningitidis. Fourteen patients had documentation of receipt of at least 1 dose of meningococcal vaccine before disease onset. Because eculizumab recipients remain at risk for meningococcal disease even after receipt of meningococcal vaccines, some health care providers in the United States as well as public health agencies in other countries recommend antimicrobial prophylaxis for the duration of eculizumab treatment; a lifelong course of treatment is expected for many patients. Heightened awareness, early care seeking, and rapid treatment of any symptoms consistent with meningococcal disease are essential for all patients receiving eculizumab treatment, regardless of meningococcal vaccination or antimicrobial prophylaxis status.
引用
- McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28704351. doi:10.15585/mmwr.mm6627e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。